The Next Five Years in Psoriasis: Remission, Access, and Combinations

In "The Next Five Years in Psoriasis: Remission, Access, and Combinations," the panel looks ahead to the advances and the unfinished work of the coming years.

Dr. Han hopes the field will embrace all components of psoriatic disease equally and reach consensus on remission for the joints, not just the skin. He points out that even very low disease activity still allows up to one joint, so the definitions themselves show how far the joint side has to go. He is encouraged that development has not truly slowed.

Dr. Han previews a next era of biologics using dual inhibition and multi-active designs that target several cytokines at once. He notes patients may soon face a once-a-year injection, something few would have believed five years ago, and stresses that even a strong landscape leaves room to improve quality of life. He returns forcefully to access, describing patients who watch drug commercials with a call to action they cannot fulfill because the nearest dermatologist is a four-hour drive and six months away.

Dr. Wright picks up the access thread, citing recent work showing that where a patient lives shapes which drug they receive first and maps onto disease burden. She calls these the social and commercial determinants of health that decide who ever gets a chance at remission.

Dr. Wright wants the field to unpack what challenging-to-manage and treatment-refractory truly mean, ideally with predictive biomarkers so patients do not cycle through drugs while damage accrues. She insists on treating the whole person, including mental health, obesity, and cardiovascular risk, summed up in her line that bones hurt but heart kills. She predicts combination therapy will be essential for complex patients, even without large randomized trials to guide it.

Thank you for watching this HCPLive Peer Exchange series on psoriasis. Please subscribe to our eNewsletter for information on upcoming video series.